Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | PDE4A | P27815 | 1/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5026183 | 0.94 | MAPT (0.54) | MAPTALDH1A1KDM4ERAB9AMAPK1 | |
| SCHEMBL5024695 | 0.89 | MAPT (0.54) | MAPTALDH1A1KDM4ERAB9AMAPK1 | |
| SCHEMBL5026135 | 0.88 | MAPT (0.52) | MAPTALDH1A1KDM4ERAB9AMAPK1 | |
| SCHEMBL4418734 | 0.87 | KDM4E (0.62) | MAPTALDH1A1KDM4ERAB9AMAPK1 | |
| SCHEMBL5043447 | 0.87 | MAPT (0.47) | MAPTALDH1A1KDM4ERAB9AMAPK1 | |
| SCHEMBL5043443 | 0.87 | MAPT (0.47) | MAPTALDH1A1KDM4ERAB9AMAPK1 | |
| SCHEMBL4426414 | 0.87 | LHCGR (0.57) | MAPTALDH1A1KDM4ERAB9AMAPK1 | |
| SCHEMBL6215323 | 0.87 | ALDH1A1 (0.66) | MAPTALDH1A1KDM4ERAB9AMAPK1 | |
| SCHEMBL6214088 | 0.85 | MAPT (0.60) | MAPTALDH1A1KDM4ERAB9AMAPK1 | |
| SCHEMBL6215827 | 0.82 | KDM4E (0.60) | MAPTALDH1A1KDM4ERAB9AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618963-B2 | Bicyclic heteroaromatic compounds | N.V. ORGANON (NL) | 2009-11-17 | — | — | US | disclosed |
| US-7375109-B2 | Glycine-substituted thieno[2,3-d]pyrimidines with combined LH and FSH agonistic activity | N.V. ORGANON (NL) | 2008-05-20 | — | — | US | disclosed |
| EP-1886999-A2 | Bicyclic heteroaromatic compound | N.V. Organon (NL) | 2008-02-13 | — | — | EP | disclosed |
| US-20070197527-A1 | Bicyclic heteroaromatic compounds | N.V. ORGANON (NL) | 2007-08-23 | — | — | US | disclosed |
| US-7229990-B2 | Bicyclic heteroaromatic compounds | N.V. ORGANON (NL) | 2007-06-12 | — | — | US | disclosed |
| CN-1247594-C | Bicyclic heteroaromatic compounds | OKZO NOBEL N V (NL) | 2006-03-29 | — | — | CN | disclosed |
| EP-1427734-B1 | GLYCINE-SUBSTITUTED THIENO[2,3-d]PYRIMIDINES WITH COMBINED LH AND FSH AGONISTIC ACTIVITY | AKZO NOBEL NV (NL) | 2005-11-09 | — | — | EP | disclosed |
| US-20040180907-A1 | Glycine-substituted thieno{2,3-d}pyrimidines with combined lh and fsh agonistic activity | MERCK SHARP & DOHME B.V. (NL) | 2004-09-16 | — | — | US | disclosed |
| CN-1462273-A | Bicyclic heteroaromatic compounds | OKZO NOBEL N V (NL) | 2003-12-17 | — | — | CN | disclosed |
| US-20030225113-A1 | Bicyclic heteroaromatic compounds | MERCK SHARP & DOHME B.V. (NL) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225113-A1 | Bicyclic heteroaromatic compounds | NR5A1, CYP19A1, FSHR | MAPT 4796/4885ALDH1A1 1372/4885KDM4E 1309/4885 |
| US-20040180907-A1 | Glycine-substituted thieno{2,3-d}pyrimidines with combined lh and fsh agonistic activity | FSHR, GNRHR, LHCGR | MAPT 4881/4885ALDH1A1 1676/4885KDM4E 1976/4885 |
| US-20070197527-A1 | Bicyclic heteroaromatic compounds | NR5A1, CYP19A1, FSHR | MAPT 4807/4885ALDH1A1 1340/4885KDM4E 1074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.